Potentiation of Th1-Type Immune Responses to Mycobacterium tuberculosis Antigens in Mice by Cationic Liposomes Combined with De-O-Acylated Lipooligosaccharide.

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. Bacillus Calmette-Guérin (BCG) vaccine is the only TB vaccine currently available, but it is not sufficiently effective in preventing active pulmonary TB or adult infection. With the purpose of developing an improved vaccine against TB that can overcome the limitations of the current BCG vaccine, we investigated whether adjuvant formulations containing de-O-acylated lipooligosaccharide (dLOS) are capable of enhancing the immunogenicity and protective efficacy of TB subunit vaccine. The results revealed that dLOS/dimethyl dioctadecyl ammonium bromide (DDA) adjuvant formulation significantly increased both humoral and Th1-type cellular responses to TB subunit vaccine that are composed of three antigens, Ag85A, ESAT-6, and HspX. The adjuvanted TB vaccine also effectively induced Th1-type response in a BCG-primed mouse model, suggesting a potential as a booster vaccine. Finally, dLOS/DDA-adjuvanted TB vaccine showed protective efficacy against M. tuberculosis infection in vitro and in vivo. These data indicate that dLOS/DDA adjuvant enhances the Th1-type immunity and protective efficacy of TB subunit vaccine suggesting that it would be a promising adjuvant candidate for development of a booster vaccine.

[1]  Courtney R. Plumlee,et al.  Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung , 2016, Mucosal Immunology.

[2]  A. Ko,et al.  A De-O-acylated Lipooligosaccharide-Based Adjuvant System Promotes Antibody and Th1-Type Immune Responses to H1N1 Pandemic Influenza Vaccine in Mice , 2016, BioMed research international.

[3]  T. Scriba,et al.  T cells and adaptive immunity to Mycobacterium tuberculosis in humans , 2015, Immunological reviews.

[4]  M. L. La Manna,et al.  Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis , 2014, Front. Immunol..

[5]  Y. Cho,et al.  Characterization of the Structure and Immunostimulatory Activity of a Vaccine Adjuvant, De-O-Acylated Lipooligosaccharide , 2014, PloS one.

[6]  G. Rhie,et al.  Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine , 2013, Archives of pharmacal research.

[7]  S. Behar.  Antigen-specific CD8(+) T cells and protective immunity to tuberculosis. , 2013, Advances in experimental medicine and biology.

[8]  A. Ramsay,et al.  Prime–boost approaches to tuberculosis vaccine development , 2012, Expert review of vaccines.

[9]  S. Kaufmann.  Tuberculosis vaccine development: strength lies in tenacity. , 2012, Trends in immunology.

[10]  Hong-Jin Kim,et al.  Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. , 2012, Vaccine.

[11]  M. Brennan,et al.  Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. , 2012, Vaccine.

[12]  J. Chun,et al.  A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice. , 2011, International immunopharmacology.

[13]  J. Posey,et al.  Cellular Immune Responses to Nine Mycobacterium tuberculosis Vaccine Candidates following Intranasal Vaccination , 2011, PloS one.

[14]  T. Ottenhoff,et al.  Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. , 2011, Vaccine.

[15]  A. Cooper,et al.  IL-17 and Th17 cells in tuberculosis. , 2010, Cytokine & growth factor reviews.

[16]  Stefan H E Kaufmann,et al.  Future vaccination strategies against tuberculosis: thinking outside the box. , 2010, Immunity.

[17]  S. Kaufmann,et al.  New vaccines for tuberculosis , 2010, The Lancet.

[18]  R. Shattock,et al.  Vaccine adjuvants: a priority for vaccine research. , 2010, Vaccine.

[19]  G. Son,et al.  A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice. , 2010, International immunopharmacology.

[20]  P. Andersen,et al.  Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells1 , 2009, The Journal of Immunology.

[21]  A. Cooper,et al.  Cell-mediated immune responses in tuberculosis. , 2009, Annual review of immunology.

[22]  S. Kim,et al.  Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen. , 2007, FEMS immunology and medical microbiology.

[23]  K. Lee,et al.  Immune Responses of Mice to Influenza Subunit Vaccine in Combination with CIA07 as an Adjuvant , 2007, Microbiology and immunology.

[24]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[25]  J. Andersson,et al.  Impaired Expression of Perforin and Granulysin in CD8+ T Cells at the Site of Infection in Human Chronic Pulmonary Tuberculosis , 2007, Infection and Immunity.

[26]  T. Ottenhoff,et al.  T-Cell Recognition of the HspX Protein of Mycobacterium tuberculosis Correlates with Latent M. tuberculosis Infection but Not with M. bovis BCG Vaccination , 2007, Infection and Immunity.

[27]  Sang-Nae Cho,et al.  Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination , 2006, Infection and Immunity.

[28]  Doo-sik Kim,et al.  A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. , 2006, Vaccine.

[29]  E. Agger,et al.  Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. , 2006, Vaccine.

[30]  S. Reed,et al.  The Protective Effect of the Mycobacterium bovis BCG Vaccine Is Increased by Coadministration with the Mycobacterium tuberculosis 72-Kilodalton Fusion Polyprotein Mtb72F in M. tuberculosis-Infected Guinea Pigs , 2004, Infection and Immunity.

[31]  S. Reed,et al.  Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein1 , 2004, The Journal of Immunology.

[32]  P. Andersen,et al.  Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines , 2004, Infection and Immunity.

[33]  C. Nacy,et al.  New tuberculosis vaccine development , 2002, Expert opinion on biological therapy.

[34]  C. H. Lee,et al.  Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. , 1999, Analytical biochemistry.

[35]  C. Dolea,et al.  World Health Organization , 1949, International Organization.